低密度脂蛋白导致动脉粥样硬化性心血管疾病:遗传学、流行病学与临床研究的共识声明
欧洲动脉粥样硬化学会共识小组评估LDL与ASCVD的因果关联,综合遗传学研究、前瞻性流行病学队列、孟德尔随机化研究及LDL降低治疗随机试验的证据。共识结论为LDL导致ASCVD。
要点
- LDL-C暴露绝对幅度与ASCVD风险呈剂量依赖性对数线性关联。
- 降低LDL-C的获益与LDL-C绝对降幅及暴露持续时间成比例。
- 遗传学研究与随机试验一致支持LDL导致ASCVD的因果结论。
核心结论
- 来自多种不同类型临床和遗传学研究的一致证据明确确立LDL导致ASCVD。
研究设计与样本
- 欧洲动脉粥样硬化学会共识小组通过评估遗传学研究、前瞻性流行病学队列研究、孟德尔随机化研究和LDL降低治疗随机试验的全部证据,评价LDL与ASCVD关联是否符合因果标准。
主要发现
- 导致LDL受体功能降低的罕见基因突变使LDL-C显著升高,并呈剂量依赖性增加ASCVD风险;导致LDL-C降低的罕见变异与相应较低的ASCVD风险相关。
- 自然随机遗传学研究和随机干预试验一致表明,任何降低血浆LDL颗粒浓度的机制均应使ASCVD事件风险降低,降低幅度与LDL-C绝对降幅及较低LDL-C暴露的累积持续时间成比例,前提是LDL-C降幅与LDL颗粒数降幅一致且无竞争性有害脱靶效应。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: To appraise the clinical and genetic evidence that low-density lipoproteins (LDLs) cause atherosclerotic cardiovascular disease (ASCVD). METHODS AND RESULTS: We assessed whether the association between LDL and ASCVD fulfils the criteria for causality by evaluating the totality of evidence from genetic studies, prospective epidemiologic cohort studies, Mendelian randomization studies, and randomized trials of LDL-lowering therapies. In clinical studies, plasma LDL burden is usually estimated by determination of plasma LDL cholesterol level (LDL-C). Rare genetic mutations that cause reduced LDL receptor function lead to markedly higher LDL-C and a dose-dependent increase in the risk of ASCVD, whereas rare variants leading to lower LDL-C are associated with a correspondingly lower risk of ASCVD. Separate meta-analyses of over 200 prospective cohort studies, Mendelian randomization studies, and randomized trials including more than 2 million participants with over 20 million person-years of follow-up and over 150 000 cardiovascular events demonstrate a remarkably consistent dose-dependent log-linear association between the absolute magnitude of exposure of the vasculature to LDL-C and the risk of ASCVD; and this effect appears to increase with increasing duration of exposure to LDL-C. Both the naturally randomized genetic studies and the randomized intervention trials consistently demonstrate that any mechanism of lowering plasma LDL particle concentration should reduce the risk of ASCVD events proportional to the absolute reduction in LDL-C and the cumulative duration of exposure to lower LDL-C, provided that the achieved reduction in LDL-C is concordant with the reduction in LDL particle number and that there are no competing deleterious off-target effects. CONCLUSION: Consistent evidence from numerous and multiple different types of clinical and genetic studies unequivocally establishes that LDL causes ASCVD.
引用
- Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017. PMID: 28444290. doi:10.1093/eurheartj/ehx144
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。